BERLIN-CHEMIE celebrates 30 years of affiliation to the MENARINI Group

BERLIN-CHEMIE celebrates 30 years of affiliation to the MENARINI Group

Chief Executive Officer Luca Lastrucci: "A success story that we have written together with our staff."

Berlin-Adlershof, 06/09/2022 – BERLIN-CHEMIE, a global pharmaceutical company headquartered in Berlin-Adlershof, today celebrated its affiliation to the MENARINI Group, which has been in place since 1992, at a staff party. The celebration at the same time serves as a reminder of over 130 years of company tradition, which BERLIN-CHEMIE is underlining as a central player in the Berlin-Brandenburg healthcare region with sales of 1.5 billion euro. Alongside the BERLIN-CHEMIE Executive Board and Alberto Giovanni Aleotti, Shareholder and Member of the Board of Directors of the MENARINI Group, selected prominent guests took part in the event, such as Michael Biel – State Secretary for Economics, Energy and Public Enterprise, Alessandra Molina – Minister Plenipotentiary of the Italian Embassy in Berlin, and Oliver Igel – Mayor of Berlin's Treptow-Köpenick borough. 

"Focusing on people, the wellbeing of patients, taking on responsibility and guaranteeing quality in every respect – these are the integral values that make up our blueprint for success and act as a solid foundation for our nearly 5,000 employees from over 30 countries where BERLIN-CHEMIE is present," said CEO Luca Lastrucci to open the celebrations. He continued: "On this day, we would first and foremost like to express our deepest gratitude to our employees for their outstanding commitment." In the future as well, BERLIN-CHEMIE will be putting its weight behind motivated and qualified personnel for the further growth of the company and is therefore showing particular dedication in the area of apprenticeships for the Berlin-Brandenburg region. 

The 30-year union between an Italian and an eastern German pharmaceutical company today is emblematic for a history that stands for joint success with respect to its multinationalism as well as its economic viability. At that time, BERLIN-CHEMIE enabled the MENARINI Group to enter the German, central and eastern European as well as central Asian markets and today makes a major contribution, accounting for around a third, to the group's sales volume, which stood at 3.922 billion euro in 2021. 

"The subsidiary BERLIN-CHEMIE is firmly anchored in MENARINI's production alliance and represents the group of companies with its diverse product portfolio consisting of, among others, cardiovascular agents, respiratory therapeutics and antidiabetics in Germany, central and eastern Europe and central Asia," Lastrucci commented. Synergy effects can be found on both sides of the Alps, as Berlin is home to one of the largest production sites worldwide as well as an important research location, both of which play a central role in the context of the group. 

At the official ceremony on company premises, the invited guests from the business community and politics held speeches that gave insights into the steady development of the capital city and the instrumental role played within it by BERLIN-CHEMIE. 




BERLIN-CHEMIE AG is an international, research-based pharmaceutical company with its head office in Berlin, Germany. The company is a subsidiary of the Italian pharmaceutical and diagnostics company MENARINI and is responsible within the group for the German, central and eastern European and central Asian markets. In the Year 2021, BERLIN-CHEMIE was employing around 5,000 staff worldwide and brought in sales of 1.5 billion euro. 

About the MENARINI Group 

The MENARINI Group, headquartered in Florence, Italy, is represented in over 140 countries worldwide and generated turnover of 3.922 billion euro in 2021. For more than 135 years, MENARINI has been investing in the development and commercial distribution of medicines to offer patients and healthcare professionals all over the world a broad product portfolio in areas including cardiovascular, respiratory, gastroenterology, metabolism, infectious diseases and anti-inflammatory/pain-relieving therapies. MENARINI is also strongly committed to the field of oncology.